logo
Mystery Tiltrotor Aircraft Emerges

Mystery Tiltrotor Aircraft Emerges

Yahoo12-02-2025

What looks to be a previously unseen vertical takeoff and landing (VTOL) capable aircraft design, with a mix of tilting and fixed rotors, has emerged at the Mojave Air & Space Port in California. Mojave is a hotbed for aviation development where testing of new and often intriguing designs, including VTOL types, regularly occurs.
Photographer Matt Hartman took the pictures seen above and below of the unusual aircraft at Mojave yesterday and posted them on social media. The aircraft was sitting outside a hangar on the eastern side of the main apron area, according to Hartman. Several aviation companies have a permanent presence at Mojave, and the U.S. military also makes use of its facilities.
and here the #EVTOL oddball of the week seen at MHV! No id or idea on this one… #avGeek #VTOL 02-10-25 pic.twitter.com/5oWXKnvWd4
— Matt Hartman (@ShorealoneFilms) February 11, 2025
No identifying markings are readily visible on the aircraft and it is unpainted in its primer coating. It is also physically anchored to the ground and hoses are seen snaking down from the nacelles holding the rotors, all of which is common to see during ground testing of VTOL designs.
From what can otherwise be seen in Hartman's pictures, the design has six rotor assemblies. There are two larger ones in tilting nacelle pods at the wingtips and two pairs of smaller ones that appear to be fixed vertically in nacelles built into the high-mounted wing. A single, horizontal trapezoidal tail points to a twin-boom tail configuration that is also visible.
There is a central fuselage with a front windscreen with two distinct halves, pointing to side-by-side seating, at least for individuals up front. A large doorway is also seen on the left side of the forward fuselage. A tricycle landing gear arrangement consisting of a nose wheel and two main wheels attached to struts sticking out from the sides of the rear of the fuselage is visible, as well. In some very broad respects, it almost looks like a mashup of the OV-10 Bronco light attack and observation aircraft and the V-22 Osprey tilt-rotor.
Though what kind of propulsion system the design might have is unknown, the wingtip nacelle pods at least have exhausts pointing to turbine engines, which could drive the rotors directly or produce electricity to run electric motors that drive these rotors. They could also drive the wing rotor via mechanical linkages or by providing electronic power to their motors. Additional turbines might also be present in the wing nacelles to provide power to those rotors, either mechanically or electrically, but they would have to be small and this seems less likely to be the case. A hybrid-electric design where turbines provide electricity to at least some of the rotors would be a particularly big deal as this is still an emerging technology space, especially for the U.S. military, if it is involved with this design at all.
The market space for hybrid and electric VTOL designs, crewed and uncrewed, and intended for civilian and/or military use, has exploded in recent years in the United States and globally. In April 2024, the independent Vertical Flight Society said its database of distinct electric VTOL, or eVTOL, concepts had hit 1,000 entries. Many such designs have been tested at Mojave.
The Air Force's Agility Prime program, which began in 2020, is perhaps the best-known example of recent U.S. military efforts in this space. Run through AFWERX, the service's internal technology incubator, Agility Prime has been experimenting with a variety of eVTOL designs, including types from Beta Technologies, Joby Aviation, and LIFT Aircraft. In December, Aviation Week reported that persistent range limitations with existing eVTOL designs had prompted Agility Prime to refocus its efforts on hybrid-electric types.
For the U.S. military, interest in new VTOL aircraft designs, including the active development of types with more traditional propulsion arrangements, is being driven in part by a desire for greater runway independence amid concerns about the growing vulnerability of air bases, as well as other established facilities, during a future high-end conflict. This, in turn, has led to the development of new concepts of operations focused heavily on expeditionary and distributed operations, including in remote and austere sites with limited existing infrastructure. New VTOL designs, especially uncrewed ones, are also increasingly viewed as important components of future supply chains for forces in forward areas, including right on the front lines. Casualty evacuation and the extraction of downed pilots, including from behind enemy lines, have also been presented as potential roles for such aircraft.
There is also considerable civilian interest in hybrid-powered and eVTOL designs, including from commercial operators eyeing them for use as air taxis.
While we don't know if the aircraft that has now emerged at Mojave is intended for civilian or military use, or both, it does appear to be quite elaborate overall. Larger tilt-rotor designs also remain rare among civilian-focused general mobility concepts.
TWZ will be keeping an eye out for more information about this VTOL aircraft and what its projected roles might be.
Contact the author: joe@twz.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Abstractive Health Launches Clinical Time Machine, the First AI Game Built on Real Historical Patient Records
Abstractive Health Launches Clinical Time Machine, the First AI Game Built on Real Historical Patient Records

Business Wire

time7 hours ago

  • Business Wire

Abstractive Health Launches Clinical Time Machine, the First AI Game Built on Real Historical Patient Records

NEW YORK--(BUSINESS WIRE)--Abstractive Health has launched Clinical Time Machine, an AI-driven simulation that immerses physicians in diagnostic cases using real historical medical charts. Built on the same HIPAA-compliant platform that powers live summarization of electronic health records (EHRs) in hospital settings, the simulation lets clinicians explore rare, complex cases from hundreds of years ago without patient risk. Abstractive Health's broader goal is to bring clinicians into meaningful, hands-on engagement with AI. Share CEO Vince Hartman calls it 'a Microsoft Flight Simulator for medicine,' enabling diagnostic training on authentic data with no need for EHR integration. 'Three years after ChatGPT, fewer than 1% of physicians have ever seen an AI full medical record summary,' he says. 'We're changing that.' Each case begins with an AI-generated summary distilled from original, centuries-old handwritten documents. Clinicians explore the structured chart, from history of present illness to labs and vitals, and receive simulated updates based on actual clinical observations. 'It's not a quiz. It's about engaging clinical reasoning in a sandbox where doctors can make decisions and learn from them,' Hartman explains. The simulation is built on Abstractive Health's existing summarization and retrieval-augmented generation (RAG) and agentic AI platform. Leveraging advanced OCR and a robust AI summarization pipeline, it can also process handwritten records and turn scribbled notes into readable clinical narratives. The summarization technology is currently being piloted at Weill Cornell Medicine in a research collaboration to assist with writing Emergency Medicine handoff notes. Abstractive Health is also preparing to roll out the experience to Canadian outpatient clinics through a partnership with Canada's WELL Health Technologies that followed an investment and distribution deal inked last year. Abstractive Health's broader goal is to bring clinicians into meaningful, hands-on engagement with AI. 'We're not just saving time - we're helping doctors think better,' Hartman says. 'This is about curiosity, growth, and elevating clinical skill.' Clinical Time Machine is available now through Abstractive's platform for free. About Abstractive Health Abstractive Health retrieves medical records, generates trusted AI summaries, and answers complex clinical questions. Its platform is used by clinicians nationwide and is currently in pilots with Well Health and Weill Cornell Medicine. A top 3 company in the 2024 VA AI Tech Sprint, Abstractive is backed by the NSF and has been featured by Forbes 30 Under 30.

Cadillac seeds its fashionable, electric brand in the heart of Paris
Cadillac seeds its fashionable, electric brand in the heart of Paris

Miami Herald

time11 hours ago

  • Miami Herald

Cadillac seeds its fashionable, electric brand in the heart of Paris

PARIS - With beautiful, branded shop windows and broad boulevards punctuated by ornate architecture, downtown Paris is the intersection of new-world fashion and old-world grandeur. Hermes, the Louvre, Dior, Domaine National du Palais-Royal, Louis Vuitton, Eglise de la Madeleine, Chanel. Cadillac's flagship European showroom has found a home here. Housed in a historic 1919 building across the street from Palais Garnier Opera House, the 122-year-old luxury brand's Cadillac City Paris showroom is a showcase of state-of-the-art automotive fashion. This week, the fashion is motorsports, as the automotive world has descended on France for the 24 Hours of Le Mans. A 690-horsepower, V-8 powered Cadillac V-Series.R Hypercar greeted shoppers, tourists and media this week as they streamed in and out of Cadillac's huge two-story store on Rue Meyerbeer - one of five European stores for the brand, including Zurich, Switzerland; Stockholm, Sweden, and Hamburg and Frankfurt, Germany. The race car is representative of Caddy's four-car assault on Le Mans as the brand tries to win the historic race 75 years after it first competed there in the 1950s. If the V8-powered V-Series.R represents the current fashion in sportscar racing, then the electric Lyriq V-Series - also introduced into the store this week - represents the state of European auto fashion. "We transformed the entire space in honor of the 24 hours of Le Mans, so we are expecting a lot of traffic to see the beautiful race car - and then watching the Le Mans race with us. We have grandstands, we have popcorn, we have big live viewing screens,' said Cadillac France Communications Director Isabelle Weitz. "And the Lyriq-V is a big introduction for us. Obviously, the performance aspect, I think, is really going to be of interest." Like the Apple Opera Store on the Rue Halevy just around the corner from Cadillac City Paris, the showroom gives off a high-tech vibe behind a historic façade. The modern, open space encircles a wrought-iron circular staircase that disappears into the ceiling on its way to the second floor. Instead of iPhones, laptops and tablets, the V-Series models are the product centerpieces. But the second floor feels very Apple Store-like with long tables full of tablets that customers can use to configure their new Cadillac - complete with colors, wheels, V-performance. It's a decidedly American high-tech feel, and the Cadilac store was filled with young families and young adults interacting with the tablets as well as the race car. "The Paris showroom is ornate outside, but feels homey on the inside for families and kids who want to spend time with the products," said popular model, social influencer and race car driver Lindsey Brewer as she conducted a photo shoot at the store. Inside, passersby signed up for Lyriq test drives - the cars pulling up to the curb for a slow drive around Paris's choked evening streets. Since the showroom opened last year, Cadillac has grown to the fourth best-selling EV maker in France. In a country where many owners (unlike in the United States) get their cars via company fleets, some of Cadillac's biggest customers include telecom, food and postal companies. Weitz said this new tech mixes nicely with a brand that - for all its years in the wilderness in the late 20th century - is integrated in European culture. Cadillacs inhabit the songs that Europeans listen to - Bruce Springsteen's "Pink Cadillac," "Cadillac Song" by Ariana Grande, Aretha Franklin's "Freeway of Love" - and the new models reinforce that image with cutting-edge Dolby Atmos tech. Cadillac even sponsors the EF Pro Cycling team - providing its Lyriq support vehicles for the Tour de France. "Unlike Jaguar, for example, that is completely reinventing itself for the electric age, Cadillac is keeping a focus on its heritage while also moving forward," said Brewer, who raced in the Indy NXT series at the Detroit Grand Prix in 2024. "It's innovating in fashion and in music." Cadillac will follow up this year's Le Mans-palooza with an even more audacious entry next year into Formula One, Europe's most prestigious open-wheel racing series. Cadillac's presence here is about more than performance, however. The brand sees a unique opportunity to recast itself as the "Standard of the World" in Europe - leaning into its roots as an innovative luxury brand with a new generation of electric cars in a country that bears its namesake. "Cadillac is named after a small town in southwest France," said Cadillac France Sales Chief Chahine Bouaiache. "We are selling our cars to Parisians who love the design of the car. The designer was a French woman," referring to Magalie Debellis, former manager of Cadillac Advanced Design who led the Lyriq styling team. Cadillac believes that its history of innovation positions itself to take advantage of new digital and electric automotive tech. The brand innovated the electric self-starter (1912), column-mounted shifter (1938), air suspension (1957), heated seats (1966), LED lighting (2000) and magnetic ride suspension (2022) - all of which the Lyriq, Optiq and Vistiq share. The Paris store leans into its history with a hallway decorated with features covering the brand's achievements organized into four sections: Innovation, La Mode (fashion), Le Cinema (Cadillac in movies), La Musique. One innovation that's missing from the EVs? Super Cruise, Cadillac's innovative, hands-free driving system that the European Union - lagging the United States - has not approved for use on its roads. "I was born in France, grew up in Germany. Cadillac, for me, is a brand that you just know, and I think that's I speak for the whole of Europe," Bouaiache said of the distinctive Lyriqs plying Paris streets. "It's one that always had incredible design innovation, technology ... it's just one that turns heads. You want to look at it." ____ Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

Yahoo

time2 days ago

  • Yahoo

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) ('Rakovina' or the 'Company'), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that members of its executive team will attend the 2025 BIO International Convention, taking place June 16th – 19th in Boston, Massachusetts. Rakovina Therapeutics' management will participate in one-on-one partnering meetings throughout the conference with leading global pharmaceutical and biotechnology companies. The Company will showcase its pipeline of novel DNA damage response (DDR) inhibitors, including drug candidates discovered through its proprietary AI-driven platforms—Deep Docking and Variational AI's generative technology. These collaborations have produced promising compounds with potential applications in DDR-targeted oncology therapies, including candidates capable of penetrating the blood-brain barrier and addressing significant unmet medical needs in the treatment of cancer. KT-3000 Series The KT-3000 series is a novel class of dual-function small molecule inhibitors combining PARP and histone deacetylase (HDAC) inhibition in a single agent. Published pre-clinical data demonstrate that lead candidates for the kt-3000 series retain anti-tumor activity in cancers that are resistant to treatment with FDA-approved PARP inhibitors. The KT-3000 program presents an attractive partnering opportunity for companies seeking to expand their oncology portfolios with multi-functional agents that can be developed across a range of solid tumor indications. Rakovina is actively exploring collaborations to accelerate development and broaden the clinical utility of this program. KT-2000AI Series The KT-2000 series features highly selective PARP1 inhibitors designed to penetrate the blood-brain-barrier, addressing a critical unmet need in the treatment of primary and metastatic brain tumors. The Company previously announced that it had used its proprietary AI algorithm to screen billions of potential drug candidates to identify potential best-in-class lead candidates. By targeting PARP1 specifically—while sparing PARP2—the KT-2000 compounds are anticipated to deliver potent anti-tumor activity with an improved safety profile. The program is well positioned for strategic partnerships focused on advancing therapies for glioblastoma and other CNS-involved cancers, where few targeted options exist. KT-5000AI Series The KT-5000 series focuses on highly selective ATR inhibitors, a key target in the DNA damage response pathway. ATR inhibition has emerged as a promising strategy to exploit tumor vulnerabilities in cancers. Rakovina's AD-derived KT-5000 candidates are engineered for optimal selectivity and tolerability, positioning them for combination use with other DDR-targeted agents or standard-of-care therapies. The program represents a significant opportunity to address a wide range of solid tumors with high unmet medical need. 'The Rakovina Therapeutics team has advanced multiple programs from discovery to pre-clinical validation in our laboratories at the University of British Columbia. We look forward to engaging with potential partners who share our vision of accelerating breakthrough therapies through the integration of artificial intelligence and oncology expertise,' said Jeffrey Bacha, Executive Chairman. 'BIO provides an opportunity to both continue and initiate strategic discussions to drive long-term value through collaboration.' Rakovina's platform has already attracted interest from multiple pharmaceutical companies seeking differentiated assets and AI-powered discovery capabilities. The Company anticipates that upcoming milestones—including lead optimization data and new target nominations—will further enhance its strategic positioning. For more information or to schedule a meeting with Rakovina Therapeutics management at BIO, please contact: Michelle Seltenrich, Director, Corporate Development – About BIO International Convention The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. In a time of remarkable discovery and progress, the biotechnology industry stands at the forefront of a revolution changing how we live, heal, and care. From pioneering treatments offering hope to millions, to sustainable agricultural innovations to feed a growing population, or environmental breakthroughs securing our future, biotech drives positive change faster than ever. This progress is not just a change but a promise for a brighter future. The world is ready. For more information: About Rakovina Therapeutics Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact:Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@ in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store